AAD 2026Abstract 74490Laboratory research
Preclinical Characterization of NAV-242, a half-life extended bispecific antibody against TNF-alpha and OX40L
Daryani N, Mack T, Rothschilds A, Chung JK, Irvine F, Zuniga L, Daryani N, Thomas S, Touzova T, Tisdale A, Grebe K
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: Cancer drugs
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.1386 · Not in PubMed: details from Crossref